| Author, year |
Study type |
Study period |
Follow-up |
Country |
Population |
Bismuth-containing quadruple therapy |
Control |
| n (M/F) |
Age |
Drug |
Therapy time |
n (M/F) |
Age |
Drug |
Therapy time |
| Calvet 1998 |
RCT |
1994.07-1996.02 |
12 months |
Spain |
Patients with PU and H. pyloripositive |
42 (35/7) |
51.9±15.51 |
O 40 mg b.i.d.;
A 2500mg once daily;
M 500 mg t.i.d.;
B 360 mg t.i.d. |
2 days |
39 (27/12) |
52.5±13.9 |
O 20 mg b.i.d.;
A 1000 mg t.i.d.;
M 500 mg t.i.d. |
14 days |
| Calvet 2002 |
RCT |
1999.04-2001.01 |
6 months |
Spain |
Patients diagnosed of PU and H. pylori |
168 (120/48) |
52.6±17.4 |
O 20 mg b.i.d.;
T 500 mg t.i.d.;
M 500 mg t.i.d.;
B: 120 mg t.i.d. |
7 days |
171 (117/54) |
51.5±15.9 |
O 20 mg b.i.d.;
A 1000 mg t.i.d.;
C 500 mg t.i.d. |
7 days |
| Kim 2013 |
RCT |
2003-2010 |
12 months |
Korea |
Patients with persistent H. pylori infection |
59 (35/24) |
56.1±9.3 |
E 20 mg b.i.d.;
M 500 mg t.i.d.;
T 500 mg q.i.d.;
B 300 mg q.i.d.; |
14 days |
116 (69/47) |
56.8±9.5 |
M 400 mg q.i.d.;
E 20 mg b.i.d.;
A 1000 mg b.i.d. |
14 days |
| Lara 2003 |
RCT |
1998.08-2000.12 |
NR |
USA |
Patients with dyspepsia and H. pylori infection |
80 (36/44) |
46±12 |
M 500 mg q.i.d.;
A 2000 mg q.i.d.;
Lan 30*2mg once;
B 262*2 mg q.i.d. |
7 day |
80 (33/47) |
53±16 |
C 500 mg b.i.d.;
A 500*2 mg b.i.d.;
Lan 30 mg b.i.d. |
7 days |
| Liao 2013 |
RCT |
2012 |
NR |
China |
Patients diagnosed of H. pylori positive |
80 (43/37) |
46.7 (23-78)2 |
Lan 30 mg b.i.d.;
A 1000 mg b.i.d.;
Lev 500 mg once;
B 220 mg b.i.d. |
14 days |
81 (46/35) |
48.9 (23-75) |
Lan 30 mg b.i.d.;
A 1000 mg b.i.d.;
Lev 500 mg once |
14 days |
| Momeni 2014 |
Double-blind RCT |
NR |
NR |
Iran |
Patients diagnosed of PU and H. pyloripositive |
30 (13/17) |
40.8±15.5 |
O 20 mg b.i.d.;
A 1000 mg b.i.d.;
M 500 mg b.i.d.;
B 262*2 mg b.i.d. |
NR |
30 (14/16) |
42.2 ± 15.8 |
M 500 mg b.i.d.;
A 1000 mg b.i.d.;
O 20 mg b.i.d.;
licorice 380 mg b.i.d. |
NR |
| Pai 2003 |
RCT |
NR |
NR |
India |
Patients with H. pylori infection |
33 (32/1) |
37.5 (18-64) |
Lan 30 mg b.i.d.;
M 400 mg t.i.d.;
T 500 mg q.i.d.;
B 120 mg q.i.d. |
10 days |
35 (32/3) |
41.5 (19-69) |
Lan 30 mg b.i.d.;
A 500 mg q.i.d.;
C 500 mg b.i.d. |
10 days |
| Raoufi 2014 |
RCT |
2012.07-2012.12 |
6 months |
Iran |
Patient with persistent dispepsia |
55 |
NR |
F 100 mg q.i.d.;
T 250 mg q.i.d.;
O 20 mg b.i.d.;
B 120 mg q.i.d. |
14 days |
55 |
NR |
O 20 mg b.i.d.;
A 1000 mg b.i.d.;
C 500 mg b.i.d. |
14 days |
| Seyedmajidi 2013 |
Double-blind RCT |
2007.03-2011.09 |
NR |
Iran |
Patients diagnosed of H. pylori positive |
110 (40/60) |
44.0±3.2 |
O 20 mg b.i.d.;
A 1000 mg b.i.d.;
M 500 mg b.i.d.;
B 240 mg b.i.d. |
14 days |
98 (55/43) |
43.3±3.3 |
O 20 mg b.i.d.;
A 1000 mg b.i.d.;
C 500 mg b.i.d. |
14 days |
| Xie 2014 |
Multi-center RCT |
2010.01-2011.06 |
NR |
China |
Patients with H. pyloriinfection |
180 (118/62) |
39.6±13.6 |
R 10 mg b.i.d.;
A 1000 mg b.i.d.;
F 100 mg b.i.d.;
B 220 mg b.i,d, |
7 days |
180 (105/75) |
41.4±12.6 |
R 10 mg b.i.d.;
A 1000 mg b.i.d.;
F 100 mg b.i.d. |
7 days |